This milestone provides third-party validation of ZEOX's technology platform which could attract research partnerships and non-dilutive funding. Monitor for future developments in the competition and potential follow-on financing.
Price Chart
Executive Summary
Zeo ScientifiX (ZEOX) announced its advancement into the semi-finals of the $101 million XPRIZE Healthspan competition, validating its regenerative biologics platform targeting aging. The company has assembled a multidisciplinary team of experts to prepare its finals application.
Key Facts
- Selected as a Qualified Team advancing into the XPRIZE Healthspan Semi-Finals stage
- Competition offers $101 million in prize money for developing therapeutics that restore function in persons aged 65-80
- Company has assembled a world-class multidisciplinary team including experts in longevity, regenerative medicine, and clinical trials
- Therapeutic platform focuses on extracellular vesicle (exosome) therapeutics targeting aging mechanisms
- Follows recent appointment as official regenerative medicine educational partner for A4M
Financial Impact
Potential access to $101 million prize pool and significant validation of technology platform
Risk Factors
- Competition is highly uncertain with no guarantee of advancing to finals or winning
- Company remains in early stages with no commercial products
- OTC listing suggests limited liquidity and higher volatility
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001829126-26-003240 |
| Document: zeoscientifix_ex99-1.htm | 0001829126-26-003240 |
| Document: 0001829126-26-003240-index-headers.html | 0001829126-26-003240 |
| Document: 0001829126-26-003240-index.html | 0001829126-26-003240 |
| Document: 0001829126-26-003240.txt | 0001829126-26-003240 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 8-K | $1.50 | awaiting T+20 | — | $1.39 (−7.33%) |
Sep 15, 2026 6w ago | 8-K | $1.36 $1.15 | ▼ −15.44% | ▼ −18.42% | $1.39 (+2.21%) |
Sep 1, 2026 8w ago | 8-K | $1.20 $1.39 | ▲ +15.83% | ▲ +14.65% | $1.39 (+15.83%) |
Aug 4, 2026 12w ago | 8-K | $1.40 $1.20 | ▼ −14.16% | ▼ −12.93% | $1.39 (−0.57%) |
Jul 21, 2026 14w ago | 8-K | $1.69 $1.55 | ▼ −8.28% | ▼ −10.85% | $1.39 (−17.75%) |
Jul 8, 2026 15w ago | 8-K | $1.80 $1.40 | ▼ −22.33% | ▼ −25.61% | $1.39 (−22.78%) |
Jul 1, 2026 16w ago | 8-K | $1.77 $1.65 | ▼ −6.78% | ▼ −4.59% | $1.39 (−21.47%) |
Jun 16, 2026 19w ago | 8-K | $1.72 $1.94 | ▲ +12.79% | ▲ +11.93% | $1.39 (−19.19%) |
Jun 9, 2026 20w ago | 8-K | $1.67 $1.80 | ▲ +7.78% | ▲ +6.39% | $1.39 (−16.77%) |
May 27, 2026 21w ago | 8-K | $1.85 $1.70 | ▼ −8.11% | ▼ −6.21% | $1.39 (−24.86%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers